X

Trial Profile

Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Selinexor (Primary)
Indications Alveolar soft part sarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Soft tissue sarcoma
Focus Adverse reactions
Acronyms SeliSarc

Most Recent Events

22 Jan 2024 Planned End Date changed from 1 Jul 2024 to 31 May 2026.
22 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 30 Nov 2025.
22 Jan 2024 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com